QIAGEN N.V. is a leading global provider of molecular diagnostics and life science research solutions. The company was founded in 1984 by Heinrich Mack and Jürgen Schumacher in Düsseldorf, Germany. Initially, QIAGEN focused on developing and manufacturing DNA purification and sample preparation technologies for research laboratories. Over the years, the company expanded its product portfolio and evolved into a prominent player in the life science and molecular diagnostics industries. QIAGEN is a publicly traded company listed on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN" and on the Frankfurt Stock Exchange (FSE) under the ticker symbol "QIA."
QIAGEN's core mission is to enable advancements in life sciences and healthcare by providing innovative solutions for sample preparation, assay technologies, and bioinformatics. The company's products and technologies are widely used by researchers, healthcare professionals, and diagnostic laboratories worldwide.
One of QIAGEN's significant contributions to the field of molecular diagnostics is its development of Polymerase Chain Reaction (PCR) technologies. PCR is a fundamental technique in molecular biology that allows the amplification of specific DNA sequences, enabling researchers and clinicians to detect and analyze genetic material more effectively.
The company's product portfolio includes a wide range of solutions, such as nucleic acid isolation and purification kits, PCR assays, next-generation sequencing (NGS) technologies, and bioinformatics software. These products have applications in various areas, including cancer research, infectious diseases, personalized medicine, and forensics.
QIAGEN has also been actively involved in partnerships and collaborations with other life science companies and healthcare organizations. These collaborations have enabled QIAGEN to expand its market reach and enhance its product offerings through access to complementary technologies and expertise.